SMSPHARMA · Healthcare · Drug Manufacturers - General
Composite scorecard: 48/100 — Quality 50 · Valuation 15 · Momentum 100
| Share price | ₹384.45 |
| Market cap | ₹3,771 Cr |
| P/E ratio | 36.1 |
| P/B ratio | 4.9 |
| ROCE | 13.8% |
| Dividend yield | 0.10% |
| Book value | ₹81.83 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹887 Cr | ₹102 Cr | 19.0% |
| 2025 | ₹783 Cr | ₹69 Cr | 18.0% |
| 2024 | ₹709 Cr | ₹50 Cr | 16.0% |
| 2023 | ₹522 Cr | ₹-7 Cr | 10.0% |
| 2022 | ₹520 Cr | ₹62 Cr | 22.0% |
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. It offers anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-aginal, and anti-ulcer products. It is also involved in contract research activities on peptides. The company exports its products to approximately 75 countries. SMS Pharmaceuticals Limited was incorporated in 1987 and is headquartered in Hyderabad, India.